{"id":"NCT01189747","sponsor":"Allergan","briefTitle":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10-01","primaryCompletion":"2011-04-01","completion":"2011-07-01","firstPosted":"2010-08-27","resultsPosted":"2013-12-03","lastUpdate":"2019-05-07"},"enrollment":446,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Lateral Canthus Rhytides","Crow's Feet Lines"],"interventions":[{"type":"BIOLOGICAL","name":"onabotulinumtoxinA","otherNames":["BOTOX®","BOTOX® Cosmetic"]},{"type":"DRUG","name":"normal saline","otherNames":[]}],"arms":[{"label":"onabotulinumtoxinA","type":"EXPERIMENTAL"},{"label":"placebo (normal saline)","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthal Rhytides).","primaryOutcome":{"measure":"Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile","timeFrame":"Baseline, Day 30","effectByArm":[{"arm":"onabotulinumtoxinA","deltaMin":25.7,"sd":null},{"arm":"Placebo (Normal Saline)","deltaMin":1.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":4,"countries":["United States","Belgium","Canada","United Kingdom"]},"refs":{"pmids":["25347451"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":220},"commonTop":[]}}